Oxybuprocaine

Oxybuprocaine

Clinical data
Trade names	Novesin(e)
AHFS/Drugs.com	International Drug Names
Pregnancy category	AU: D
Routes of administration	Topical
ATC code	D04AB03 (WHO) S01HA02 (WHO)
Pharmacokinetic data
Metabolism	Esterases in blood plasma and liver
Identifiers
IUPAC name 2-diethylaminoethyl 4-amino-3-butoxy-benzoate
CAS Number	99-43-4 Y
PubChem (CID)	4633
IUPHAR/BPS	7123
DrugBank	DB00892 Y
ChemSpider	4472 Y
UNII	AXQ0JYM303 Y
KEGG	D08319 Y
ChEBI	CHEBI:309594 Y
ChEMBL	CHEMBL1200 Y
Chemical and physical data
Formula	C17H28N2O3
Molar mass	308.41 g/mol
3D model (Jmol)	Interactive image
SMILES O=C(OCCN(CC)CC)c1cc(OCCCC)c(cc1)N
InChI InChI=1S/C17H28N2O3/c1-4-7-11-21-16-13-14(8-9-15(16)18)17(20)22-12-10-19(5-2)6-3/h8-9,13H,4-7,10-12,18H2,1-3H3 Y Key:CMHHMUWAYWTMGS-UHFFFAOYSA-N Y

Oxybuprocaine (INN), also known as benoxinate or BNX, is an ester-type local anesthetic, which is used especially in ophthalmology and otolaryngology. Oxybuprocaine is sold by Novartis under the brand names Novesine or Novesin.

Safety for use in pregnancy and lactation has not been established.

Anaesthesia starts with a latency of 30 to 50 seconds and lasts for about 10 to 30 minutes, depending on perfusion. The drug is metabolised by esterases in blood plasma and liver.

When used excessively, oxybuprocaine like any other topical anesthetic used in the eye and on mucous membranes (like for example tetracaine, proxymetacaine and proparacaine) can cause irritation, hypersensitivity, anaphylaxis, irreversible corneal damage and even complete destruction of the cornea. (Excessive use means several times a day during several days or even weeks.)

Oxybuprocaine is incompatible with silver and mercury salts, as well as basic substances. It also reduces the antimicrobial action of sulfonamides.